Abstract: An electrical power conversion system for converting a high voltage from a HV electrical power supply to a low voltage is disclosed. In an embodiment, the electrical power conversion system includes at least one power converter and at least one RC network including a plurality of resistive components and a plurality of capacitive components electrically connected in series. In an embodiment, the at least one RC network is in series connection with the at least one power converter and the at least one RC network and at least one power converter are arranged to be connected across a line potential of the HV electrical power supply.

Abstract: An electrical power conversion system for converting a high voltage from a HV electrical power supply to a low voltage is disclosed. In an embodiment, the electrical power conversion system includes at least one power converter and at least one RC network including a plurality of resistive components and a plurality of capacitive components electrically connected in series. In an embodiment, the at least one RC network is in series connection with the at least one power converter and the at least one RC network and at least one power converter are arranged to be connected across a line potential of the HV electrical power supply.

Abstract: An electrical isolator includes a body defining an aperture therethrough, a first electrical contact disposed at a first end of the aperture, a second electrical contact movably disposed at a second end of the aperture, the second contact configured to be operatively movable through the aperture to electrically connect to, or disconnect from, the first contact and at least two concave electrical field control screens fixed to the body at respective ends of, and about, the aperture such that the screens lie transverse to the aperture and an open-end of each concave screen is directed towards the other.

Abstract: An electrical isolator includes a body defining an aperture therethrough, a first electrical contact disposed at a first end of the aperture, a second electrical contact movably disposed at a second end of the aperture, the second contact configured to be operatively movable through the aperture to electrically connect to, or disconnect from, the first contact and at least two concave electrical field control screens fixed to the body at respective ends of, and about, the aperture such that the screens lie transverse to the aperture and an open-end of each concave screen is directed towards the other.

Abstract: A piezoelectric actuator including a piezoelectric element and an elongate transducer mounted on the piezoelectric element. The transducer is formed from an elongate cylindrical member, and at least one helical slot is provided around the outer surface of the cylindrical member to enable coupling of resonance modes of the transducer when actuated by the piezoelectric element.

Abstract: A piezoelectric actuator including a piezoelectric element and an elongate transducer mounted on the piezoelectric element. The transducer is formed from an elongate cylindrical member, and at least one helical slot is provided around the outer surface of the cylindrical member to enable coupling of resonance modes of the transducer when actuated by the piezoelectric element.

Abstract: A system receives suspect traffic information pertaining to possible network threats. A router detects and redirects suspect traffic from within a subnetwork to an interrogation module. The interrogation module receives the redirected suspect traffic and identifies the source device from within the subnetwork. The interrogation module can also identify the type of suspect traffic, the original destination of the suspect traffic and the protocol type of the packet. Suspect traffic information can be updated and the router can be reconfigured to accommodate the updated information.

Abstract: Compounds of peptide mimetic nature having the general formula I wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: Compounds of peptide mimetic nature having the general formula I wherein a and b are independently 1 or 2, R1 and R2 are independently H or C1-6alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: Compounds of peptide mimetic nature having the general formula I formula I 1

Abstract: Compounds of peptide mimetic nature having the general formula I 1

Abstract: The present invention relates to the use of small organic compounds acting as opioid receptor ligands for the treatment of vasomotor disturbances. In particular the present invention relates to the use of triaza-spiro compounds of formula wherein R1, R2, R3, R4, R5, z and n are defined in the specification, for the treatment of migraine, non-insulin dependent diabetes mellitus (type II diabetes), sepsis, inflammation, incontinence and/or vasomotor disturbances, in particular the peripheral vasomotor effects known as hot flushes or hot flashes.

Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonising peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.

Abstract: Compounds of peptide mimetic nature having the general formula I ##STR1## wherein a and b are independently 1 or 2, R.sup.1 and R.sup.2 are independently H or C.sub.1-6 alkyl, G and J are independently, inter alia, aromats, and D and E are independently several different groups are growth hormone secretagogous with improved bioavailability.

Abstract: The present invention relates to 1,4-disubstituted piperazines of the general formula ##STR1## wherein X, Y, Z, R.sup.1, R.sup.2 and r are as defined in the detailed part of the present description or salts thereof, to methods for their preparation, to compositions containing them, and to their use for the clinical treatment of painful, hyperalgesic and/or inflammatory conditions in which C-fibers play a pathophysiological role by eliciting neurogenic pain or inflammation as well as their use for the treatment of indications caused by or related to the secretion and circulation of insulin antagonizing peptides, e.g. non-insulin-dependent diabetes mellitus (NIDDM) and ageing-associated obesity.